News Column

Interim Report, Q2 and H1 2014

August 25, 2014



CORTENDO REPORTS RESULTS AND ACTIVITIES FOR THE Q2 AND H1 OF 2014

HIGHLIGHTS - H1’2014 AND POST PERIOD

· First patient enrolled into the NormoCort™ Phase 3 SONICS trial - continued progress on trial implementation.The internal and external NormoCort development team has been further strengthened

· Matthew Pauls recruited as new CEO – effective Aug 25

· Strategic review to further strengthen focus on orphan drugs and metabolic disease

· Net loss for the Group was SEK 8.6 (5.6) million in Q2’2014 (Q2’2013) and SEK 19.8 (9.7) million in H1’2014 (H1’2013), reflecting increased R&D activities

· Cash and cash equivalents amounted to SEK 75.4 million, compared to SEK 31.6 million at 30 June 2013 and SEK 97.1 million at the end of December 2013

· Cortendo is currently preparing for and is targeting an Initial Public Offering and listing on the Oslo Stock Exchange during Q4’2014

For the full report see attached pdf-file.



This information was brought to you by Cision http://news.cision.com

http://news.cision.com/cortendo-ab/r/interim-report--q2-and-h1-2014,c9633067

The following files are available for download:

http://mb.cision.com/Main/8707/9633067/278462.pdf


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Cision


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters